[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,849,071
  • Shares Outstanding, K 834,667
  • Annual Sales, $ 3,580 M
  • Annual Income, $ 456,000 K
  • EBIT $ 539 M
  • EBITDA $ 759 M
  • 60-Month Beta 0.25
  • Price/Sales 2.65
  • Price/Cash Flow 13.43
  • Price/Book 2.34

Options Overview Details

View History
  • Implied Volatility 46.29% (-1.15%)
  • Historical Volatility 45.74%
  • IV Percentile 38%
  • IV Rank 3.63%
  • IV High 815.48% on 11/28/25
  • IV Low 17.36% on 09/02/25
  • Expected Move (DTE 27) 0.60 (5.05%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 1,008
  • Open Int (30-Day) 902
  • Expected Range 11.20 to 12.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.17
  • Number of Estimates 1
  • High Estimate $0.17
  • Low Estimate $0.17
  • Prior Year $0.19
  • Growth Rate Est. (year over year) -10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.36 +3.79%
on 07/22/26
15.67 -24.76%
on 06/26/26
-2.87 (-19.58%)
since 06/24/26
3-Month
11.36 +3.79%
on 07/22/26
15.67 -24.76%
on 06/26/26
-1.88 (-13.75%)
since 04/24/26
52-Week
11.36 +3.79%
on 07/22/26
15.67 -24.76%
on 06/26/26
-2.92 (-19.85%)
since 07/24/25

Most Recent Stories

More News
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reaction...

RDY : 11.79 (+0.63%)
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in...

RDY : 11.79 (+0.63%)
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets...

RDY : 11.79 (+0.63%)
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28 th , 2026, marking the company’s readiness to serve Canadian patients...

RDY : 11.79 (+0.63%)
Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide...

RDY : 11.79 (+0.63%)
Dr. Reddy's Reports Tuesday With Semaglutide Approval Still Awaiting Commercial Impact

Barchart Research What to Expect from RDY Earnings RDY Generated May 7, 2026 Current Price $13.43 EPS Estimate $$0.09 Consensus Rating Moderate Sell Average Move 2.59% Dr. Reddy's Reports Tuesday With...

RDY : 11.79 (+0.63%)
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

Dr. Reddy’s becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada The market authorization was granted...

RDY : 11.79 (+0.63%)
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Following the submission in December 2025, USFDA has accepted Dr. Reddy’s 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) ...

RDY : 11.79 (+0.63%)
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine...

RDY : 11.79 (+0.63%)
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts...

RDY : 11.79 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through...

See More

Key Turning Points

3rd Resistance Point 12.26
2nd Resistance Point 12.12
1st Resistance Point 11.96
Last Price 11.79
1st Support Level 11.65
2nd Support Level 11.51
3rd Support Level 11.35

See More

52-Week High 15.67
Fibonacci 61.8% 14.02
Fibonacci 50% 13.51
Fibonacci 38.2% 13.01
Last Price 11.79
52-Week Low 11.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.